NVP-2, in combination with Orlistat, represents a promising therapeutic strategy for acute myeloid leukemia
Cell cycle dysregulation and the corresponding metabolic reprogramming play significant roles in tumor development and progression. CDK9, a kinase that regulates gene transcription and cell cycle, also induces oncogene transcription and abnormal cell cycle in AML cells. The function of CDK9 for gene...
Saved in:
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2025-12-01
|
| Series: | Cancer Biology & Therapy |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/15384047.2025.2450859 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841544046650064896 |
|---|---|
| author | Qing Zhu Jia Cheng Yuqing Gao Zimu Zhang Jian Pan Xin Su Danhong Fei Linbo Cai Juanjuan Yu Yanling Chen Wanyan Jiao Di Wu Xiaolu Li Peifang Xiao |
| author_facet | Qing Zhu Jia Cheng Yuqing Gao Zimu Zhang Jian Pan Xin Su Danhong Fei Linbo Cai Juanjuan Yu Yanling Chen Wanyan Jiao Di Wu Xiaolu Li Peifang Xiao |
| author_sort | Qing Zhu |
| collection | DOAJ |
| description | Cell cycle dysregulation and the corresponding metabolic reprogramming play significant roles in tumor development and progression. CDK9, a kinase that regulates gene transcription and cell cycle, also induces oncogene transcription and abnormal cell cycle in AML cells. The function of CDK9 for gene regulation in AML cells requires further exploration. In this study, we knocked down the CDK9 to investigate its effects on the growth and survival of AML cells. Through RNA-seq analysis, we identified that in U937 cells CDK9 regulates numerous genes involved in proliferation and apoptosis, including mTOR, SREBF1, and Bcl-2. Furthermore, our results demonstrated that both CDK9 and FASN are crucial for the proliferation and survival of Kasumi-1 and U937 cells. Mechanistically, MCL1, c-Myc, and Akt/mTOR/SREBF1 may be critical factors and pathways in the combined therapy of NVP-2 and Orlistat. In summary, our study revealed that CDK9 and FASN are vital for maintaining AML cell survival and proliferation. Treatment with NVP-2 and Orlistat may be a promising clinical candidate for patients with AML. |
| format | Article |
| id | doaj-art-8f96f96f8b0c47f7b3c82a6960054a73 |
| institution | Kabale University |
| issn | 1538-4047 1555-8576 |
| language | English |
| publishDate | 2025-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Cancer Biology & Therapy |
| spelling | doaj-art-8f96f96f8b0c47f7b3c82a6960054a732025-01-13T04:09:53ZengTaylor & Francis GroupCancer Biology & Therapy1538-40471555-85762025-12-0126110.1080/15384047.2025.2450859NVP-2, in combination with Orlistat, represents a promising therapeutic strategy for acute myeloid leukemiaQing Zhu0Jia Cheng1Yuqing Gao2Zimu Zhang3Jian Pan4Xin Su5Danhong Fei6Linbo Cai7Juanjuan Yu8Yanling Chen9Wanyan Jiao10Di Wu11Xiaolu Li12Peifang Xiao13Children’s Hospital of Soochow University, Suzhou, ChinaChildren’s Hospital of Soochow University, Suzhou, ChinaInstitute of Pediatric Research, Children’s Hospital of Soochow University, Suzhou, ChinaInstitute of Pediatric Research, Children’s Hospital of Soochow University, Suzhou, ChinaInstitute of Pediatric Research, Children’s Hospital of Soochow University, Suzhou, ChinaDepartment of Hematology, Children’s Hospital of Soochow University, Suzhou, ChinaChildren’s Hospital of Soochow University, Suzhou, ChinaChildren’s Hospital of Soochow University, Suzhou, ChinaChildren’s Hospital of Soochow University, Suzhou, ChinaChildren’s Hospital of Soochow University, Suzhou, ChinaChildren’s Hospital of Soochow University, Suzhou, ChinaInstitute of Pediatric Research, Children’s Hospital of Soochow University, Suzhou, ChinaInstitute of Pediatric Research, Children’s Hospital of Soochow University, Suzhou, ChinaDepartment of Hematology, Children’s Hospital of Soochow University, Suzhou, ChinaCell cycle dysregulation and the corresponding metabolic reprogramming play significant roles in tumor development and progression. CDK9, a kinase that regulates gene transcription and cell cycle, also induces oncogene transcription and abnormal cell cycle in AML cells. The function of CDK9 for gene regulation in AML cells requires further exploration. In this study, we knocked down the CDK9 to investigate its effects on the growth and survival of AML cells. Through RNA-seq analysis, we identified that in U937 cells CDK9 regulates numerous genes involved in proliferation and apoptosis, including mTOR, SREBF1, and Bcl-2. Furthermore, our results demonstrated that both CDK9 and FASN are crucial for the proliferation and survival of Kasumi-1 and U937 cells. Mechanistically, MCL1, c-Myc, and Akt/mTOR/SREBF1 may be critical factors and pathways in the combined therapy of NVP-2 and Orlistat. In summary, our study revealed that CDK9 and FASN are vital for maintaining AML cell survival and proliferation. Treatment with NVP-2 and Orlistat may be a promising clinical candidate for patients with AML.https://www.tandfonline.com/doi/10.1080/15384047.2025.2450859Acute myeloid leukemiaapoptosisCDK9cell proliferationc-MycFASN |
| spellingShingle | Qing Zhu Jia Cheng Yuqing Gao Zimu Zhang Jian Pan Xin Su Danhong Fei Linbo Cai Juanjuan Yu Yanling Chen Wanyan Jiao Di Wu Xiaolu Li Peifang Xiao NVP-2, in combination with Orlistat, represents a promising therapeutic strategy for acute myeloid leukemia Cancer Biology & Therapy Acute myeloid leukemia apoptosis CDK9 cell proliferation c-Myc FASN |
| title | NVP-2, in combination with Orlistat, represents a promising therapeutic strategy for acute myeloid leukemia |
| title_full | NVP-2, in combination with Orlistat, represents a promising therapeutic strategy for acute myeloid leukemia |
| title_fullStr | NVP-2, in combination with Orlistat, represents a promising therapeutic strategy for acute myeloid leukemia |
| title_full_unstemmed | NVP-2, in combination with Orlistat, represents a promising therapeutic strategy for acute myeloid leukemia |
| title_short | NVP-2, in combination with Orlistat, represents a promising therapeutic strategy for acute myeloid leukemia |
| title_sort | nvp 2 in combination with orlistat represents a promising therapeutic strategy for acute myeloid leukemia |
| topic | Acute myeloid leukemia apoptosis CDK9 cell proliferation c-Myc FASN |
| url | https://www.tandfonline.com/doi/10.1080/15384047.2025.2450859 |
| work_keys_str_mv | AT qingzhu nvp2incombinationwithorlistatrepresentsapromisingtherapeuticstrategyforacutemyeloidleukemia AT jiacheng nvp2incombinationwithorlistatrepresentsapromisingtherapeuticstrategyforacutemyeloidleukemia AT yuqinggao nvp2incombinationwithorlistatrepresentsapromisingtherapeuticstrategyforacutemyeloidleukemia AT zimuzhang nvp2incombinationwithorlistatrepresentsapromisingtherapeuticstrategyforacutemyeloidleukemia AT jianpan nvp2incombinationwithorlistatrepresentsapromisingtherapeuticstrategyforacutemyeloidleukemia AT xinsu nvp2incombinationwithorlistatrepresentsapromisingtherapeuticstrategyforacutemyeloidleukemia AT danhongfei nvp2incombinationwithorlistatrepresentsapromisingtherapeuticstrategyforacutemyeloidleukemia AT linbocai nvp2incombinationwithorlistatrepresentsapromisingtherapeuticstrategyforacutemyeloidleukemia AT juanjuanyu nvp2incombinationwithorlistatrepresentsapromisingtherapeuticstrategyforacutemyeloidleukemia AT yanlingchen nvp2incombinationwithorlistatrepresentsapromisingtherapeuticstrategyforacutemyeloidleukemia AT wanyanjiao nvp2incombinationwithorlistatrepresentsapromisingtherapeuticstrategyforacutemyeloidleukemia AT diwu nvp2incombinationwithorlistatrepresentsapromisingtherapeuticstrategyforacutemyeloidleukemia AT xiaoluli nvp2incombinationwithorlistatrepresentsapromisingtherapeuticstrategyforacutemyeloidleukemia AT peifangxiao nvp2incombinationwithorlistatrepresentsapromisingtherapeuticstrategyforacutemyeloidleukemia |